Phase 1–2 trial of antisense oligonucleotide tofersen for SOD1 ALS

Authors

Timothy Miller, Washington University School of Medicine in St. Louis
Robert C. Bucelli, Washington University School of Medicine in St. Louis
Alan Pestronk, Washington University School of Medicine in St. Louis
et al.

Journal

New England Journal of Medicine

Publication Date

2020

Volume

383

Issue

2

First Page

109

Last Page

119

Document Type

Open Access Publication

DOI

10.1056/NEJMoa2003715

Rights and Permissions

Miller, T., Cudkowicz, M., Shaw, P. J., Andersen, P. M., Atassi, N., Bucelli, R. C., . . . Ferguson, T. A. (2020). Phase 1-2 trial of antisense oligonucleotide tofersen for SOD1 ALS. New England Journal of Medicine, 383(2), 109-119. doi:10.1056/NEJMoa2003715 Copyright © 2020 Massachusetts Medical Society. All rights reserved.

Recommended Citation

Miller, Timothy; Bucelli, Robert C.; Pestronk, Alan; and al., et, "Phase 1–2 trial of antisense oligonucleotide tofersen for SOD1 ALS." New England Journal of Medicine. 383, 2. 109 - 119. (2020).
https://digitalcommons.wustl.edu/open_access_pubs/9203